In this review:
This review is a summary of evidence for febuxostat (Adenuric®) as urate-lowering therapy for the treatment of gout. Febuxostat is an orally-administered xanthine oxidase inhibitor that blocks the production of urate. Febuxostat is indicated for the treatment of chronic hyperuricaemia in adults with gout (including a history, or presence of, tophus and/or gouty arthritis).
Please login below to download this issue (PDF)